Cargando…
Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires
Monoclonal antibodies (mAbs) are an important class of therapeutics used to treat cancer, inflammation, and infectious diseases. Identifying highly developable mAb sequences in silico could greatly reduce the time and cost required for therapeutic mAb development. Here, we present position-specific...
Autores principales: | Petersen, Brian M., Ulmer, Sophia A., Rhodes, Emily R., Gutierrez-Gonzalez, Matias F., Dekosky, Brandon J., Sprenger, Kayla G., Whitehead, Timothy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503325/ https://www.ncbi.nlm.nih.gov/pubmed/34646268 http://dx.doi.org/10.3389/fimmu.2021.728694 |
Ejemplares similares
-
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
por: Vaisman-Mentesh, Anna, et al.
Publicado: (2020) -
Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens
por: de Souza, Matheus Oliveira, et al.
Publicado: (2022) -
Common framework mutations impact antibody interfacial dynamics and flexibility
por: Rhodes, Emily R., et al.
Publicado: (2023) -
From rabbit antibody repertoires to rabbit monoclonal antibodies
por: Weber, Justus, et al.
Publicado: (2017) -
Monoclonal Antibodies Approved for Cancer Therapy
por: Baldo, Brian A.
Publicado: (2016)